Amplo Biotechnology
Diseases of the neuromuscular junction have profound health effects including paralysis, breathing and swallowing difficulties. Amplo Biotechnology plans to develop multiple, potentially curative, Adeno-Associated Viral (AAV) therapies for the neuromuscular junction with an initial focus on congenital myasthenic syndromes. Amplo’s lead program, AAV-Dok7, was developed by Professor Yuji Yamanashi's group of the Institute of Medical Science at the University of Tokyo, and is applicable to multiple rare, severe diseases.
Domain
amplobiotechnology.com
Country
United StatesIndustry
BiotechnologyEmployees
1-10
Last Funding
$2.9M
Founded
2018
Tech Stack (5 technologies)
Frequently Asked Questions
What technologies does Amplo Biotechnology use?+
Amplo Biotechnology uses 5 technologies including Canva, Cloudflare, HSTS.
What industry is Amplo Biotechnology in?+
Amplo Biotechnology operates in the Biotechnology industry.
Where is Amplo Biotechnology based?+
Amplo Biotechnology is headquartered in United States.
Explore More
Need this data at scale?
Get ready-to-use datasets: companies, technologies, and tech adoption signals across 3M+ websites.
Browse DatasetsData last updated: June 2026